Vanguard Group’s MacroGenics MGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$6.81M Buy
4,226,941
+2,707
+0.1% +$4.26K ﹤0.01% 3139
2025
Q3
$7.1M Buy
4,224,234
+11,120
+0.3% +$18K ﹤0.01% 3154
2025
Q2
$5.1M Sell
4,213,114
-212,878
-5% -$309K ﹤0.01% 3210
2025
Q1
$5.62M Buy
4,425,992
+109,311
+3% +$286K ﹤0.01% 3120
2024
Q4
$14M Sell
4,316,681
-40,859
-0.9% -$147K ﹤0.01% 2771
2024
Q3
$14.3M Buy
4,357,540
+222,221
+5% +$866K ﹤0.01% 2777
2024
Q2
$17.6M Buy
4,135,319
+457,641
+12% +$4.46M ﹤0.01% 2635
2024
Q1
$54.1M Sell
3,677,678
-631,716
-15% -$9.55M ﹤0.01% 2135
2023
Q4
$41.5M Sell
4,309,394
-105,530
-2% -$730K ﹤0.01% 2262
2023
Q3
$20.6M Buy
4,414,924
+36,396
+0.8% +$181K ﹤0.01% 2541
2023
Q2
$23.4M Sell
4,378,528
-89,871
-2% -$554K ﹤0.01% 2527
2023
Q1
$32M Buy
4,468,399
+24,035
+0.5% +$145K ﹤0.01% 2386
2022
Q4
$29.8M Buy
4,444,364
+262,123
+6% +$1.44M ﹤0.01% 2432
2022
Q3
$14.5M Buy
4,182,241
+251,279
+6% +$961K ﹤0.01% 2771
2022
Q2
$11.6M Sell
3,930,962
-101,277
-3% -$532K ﹤0.01% 2915
2022
Q1
$35.5M Buy
4,032,239
+86,061
+2% +$950K ﹤0.01% 2474
2021
Q4
$63.3M Buy
3,946,178
+50,038
+1% +$942K ﹤0.01% 2220
2021
Q3
$81.6M Sell
3,896,140
-44,924
-1% -$1.08M ﹤0.01% 2095
2021
Q2
$106M Buy
3,941,064
+106,790
+3% +$3.13M ﹤0.01% 1971
2021
Q1
$122M Buy
3,834,274
+258,690
+7% +$6.28M ﹤0.01% 1844
2020
Q4
$81.7M Buy
3,575,584
+274,797
+8% +$6.33M ﹤0.01% 1937
2020
Q3
$83.1M Buy
3,300,787
+18,903
+0.6% +$516K ﹤0.01% 1785
2020
Q2
$91.6M Buy
3,281,884
+32,556
+1% +$566K ﹤0.01% 1727
2020
Q1
$18.9M Buy
3,249,328
+39,798
+1% +$361K ﹤0.01% 2311
2019
Q4
$34.9M Sell
3,209,530
-3,317
-0.1% -$32.8K ﹤0.01% 2274
2019
Q3
$41M Buy
3,212,847
+14,633
+0.5% +$211K ﹤0.01% 2166
2019
Q2
$54.3M Buy
3,198,214
+161,920
+5% +$2.78M ﹤0.01% 2061
2019
Q1
$54.6M Buy
3,036,294
+485,167
+19% +$8.39M ﹤0.01% 2043
2018
Q4
$32.4M Buy
2,551,127
+280,586
+12% +$4.71M ﹤0.01% 2235
2018
Q3
$48.7M Buy
2,270,541
+165,937
+8% +$3.54M ﹤0.01% 2156
2018
Q2
$43.5M Buy
2,104,604
+415,381
+25% +$9.36M ﹤0.01% 2193
2018
Q1
$42.5M Buy
1,689,223
+124,567
+8% +$3.03M ﹤0.01% 2156
2017
Q4
$29.7M Buy
1,564,656
+44,249
+3% +$826K ﹤0.01% 2323
2017
Q3
$28.1M Buy
1,520,407
+129,085
+9% +$2.24M ﹤0.01% 2329
2017
Q2
$24.4M Buy
1,391,322
+38,458
+3% +$734K ﹤0.01% 2372
2017
Q1
$25.2M Buy
1,352,864
+44,680
+3% +$862K ﹤0.01% 2346
2016
Q4
$26.7M Buy
1,308,184
+10,025
+0.8% +$252K ﹤0.01% 2278
2016
Q3
$38.8M Buy
1,298,159
+5,957
+0.5% +$177K ﹤0.01% 2048
2016
Q2
$34.9M Buy
1,292,202
+149,611
+13% +$3.37M ﹤0.01% 2060
2016
Q1
$21.4M Buy
1,142,591
+41,537
+4% +$791K ﹤0.01% 2278
2015
Q4
$34.1M Buy
1,101,054
+25,017
+2% +$760K ﹤0.01% 2064
2015
Q3
$23M Buy
1,076,037
+273,498
+34% +$8.58M ﹤0.01% 2225
2015
Q2
$30.5M Buy
802,539
+83,091
+12% +$2.73M ﹤0.01% 2172
2015
Q1
$22.6M Buy
719,448
+148,918
+26% +$5.05M ﹤0.01% 2275
2014
Q4
$20M Buy
570,530
+3,903
+0.7% +$97.3K ﹤0.01% 2238
2014
Q3
$11.8M Buy
566,627
+177,983
+46% +$3.68M ﹤0.01% 2419
2014
Q2
$8.45M Buy
388,644
+146,560
+61% +$3.08M ﹤0.01% 2579
2014
Q1
$6.74M Buy
242,084
+118,588
+96% +$4.19M ﹤0.01% 2678
2013
Q4
$3.39M Buy
+123,496
New +$3.23M ﹤0.01% 2973

Other funds holding MGNX

Vanguard Group's MGNX Position: Q4 2025 in Review

Vanguard Group increased its MacroGenics (MGNX) stake by 0.06% in Q4 2025, buying an estimated $4.26K and bringing the position to 4,226,941 shares worth $6.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3139.

Vanguard Group first reported a position in MGNX in Q4 2013 and has held it in 49 quarters since. The position peaked at $122M in Q1 2021. 88 funds tracked by Wall St. Rank hold MGNX as of Q4 2025.

  • Vanguard Group held 4,226,941 shares of MacroGenics worth $6.81M as of Q4 2025.
  • Vanguard Group bought 2,707 MacroGenics shares in Q4 2025, an estimated $4.26K.
  • MacroGenics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3139 holding.
  • Vanguard Group first reported a position in MacroGenics in Q4 2013 and has held it in 49 quarters since.
  • Vanguard Group's MacroGenics position peaked at $122M in Q1 2021.
  • 88 funds tracked by Wall St. Rank held MacroGenics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.